Prevalence of HER-2 and Hormone Receptors and P53 Mutations in the Pathologic Specimens of Breast Cancer Patients
| Autor: | Soheila Yadollah-Damavandi, Seyed Alireza Salimi Tabatabaee, Maryam Hajilou, Tina Parsa, Seyed Abbas Mirmalek, Yekta Parsa |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Gynecology
Oncology Cancer Research medicine.medical_specialty medicine.diagnostic_test Article Subject business.industry Incidence (epidemiology) Estrogen receptor Cancer medicine.disease Malignancy lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens lcsh:RC254-282 Breast cancer screening Breast cancer Hormone receptor Internal medicine Progesterone receptor medicine Pharmacology (medical) business skin and connective tissue diseases Research Article |
| Zdroj: | International Journal of Breast Cancer International Journal of Breast Cancer, Vol 2014 (2014) |
| ISSN: | 2090-3189 2090-3170 |
| Popis: | Prognostic factors are in interest for breast cancer as the second cause of malignancy deaths. Some have predictive values as human epidermal growth factor receptor-2 (HER-2) and estrogen receptor (ER). To access the incidence of HER2 and its relations to other factors, like age, pathology, ER, progesterone receptor (PR), and P53, 2000 pathologic blocks from 2750 total samples have been selected from 2011 to 2013 in Cancer Institute of Tehran. Incidence of HER2, ER, PR, and P53 was; 58.5%, 33.4%, 43.3%, and 65.4%, respectively. Invasive ductal carcinoma was the most pathologic type (82.2%) and 60%–70% positive HER2 and P53 had negative ER and PR (poor prognosis). The peak age of incidence of breast cancer was perimenopausal age group (46–55 years). Our cases had more positive HER2 and P53 and less positive PR and ER compared to other studies. High perimenopausal incidence as another finding assures the importance of breast cancer screening in these age groups. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text